Dupixent® Retail Price Slashed Ahead of National Reimbursement Implementation to Benefit Atopic Dermatitis Patients Sooner
Sanofi
Pharmaceutical R&D Developer
Beijing, January 28, 2021 /PRNewswire/ -- The highly anticipated adjustments to the National Reimbursement Drug List have recently been finalized. Among them,WoundNew Drug Dupixent®(Dupixent Injection) has been officially included in the National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2020 Edition). It is the only targeted biologic agent for the treatment of moderate-to-severe atopic dermatitis in the new reimbursement list, indicated for patients with moderate-to-severe atopic dermatitis who are unresponsive to conventional therapies, have contraindications, or are intolerant.
Included in the National Reimbursement Drug List just five months after its market launch,Developed by Sanofi (China)Dupixent®Every step from approval and market launch to inclusion in the national reimbursement drug list exemplifies the “China speed” in accelerating access to innovative medicines, serving as a concrete testament to China’s accelerated introduction of breakthrough innovative drugs to meet urgent clinical needs. Prior to the formal implementation of the new edition of the national reimbursement drug list, and aiming to alleviate the medication burden for patients with atopic dermatitis, improve medication accessibility, and promote standardized treatment, effective January 25, 2021,Relevant retail pharmacies will significantly reduce the retail price of Dupixent., benefiting Chinese patients earlier.
Atopic Dermatitis Is More Than Just a Skin Disease, Dupixent®Reduced annual recurrence rate by nearly80%
In recent years, there has been a growing trend in immune-related diseases such as allergies and inflammation. Among these, moderate-to-severe Atopic Dermatitis (AD), primarily caused by type 2 inflammatory responses, is not only a skin disease but also a systemic immune disorder. Patients suffer from long-term intense itching, severe skin lesions, and sleep disruptions, which significantly impact their quality of life, making it the skin disease with the highest burden among non-fatal conditions.[1]“Atopic dermatitis often presents as the initial disease in the ‘skin–gastrointestinal tract–respiratory tract’ allergic march. Early onset of atopic dermatitis often indicates a higher risk of developing other type 2 inflammatory diseases, such as allergic rhinitis and asthma, in the future,” pointed out Professor Zhang Jianzhong, Director of the Department of Dermatology at Peking University People’s Hospital.
Feng Yufei, Director of the Department of Pharmacy at Peking University People's Hospital, introduced: “The targeted biologic agent Dupixent”®Unlike conventional therapies, it can specifically block key pathogenic factors of atopic dermatitis, treating type 2 inflammatory diseases mechanistically, rapidly, significantly, and sustainably improving skin lesions and pruritus symptoms, without requiring the pre-treatment screenings previously necessary for biologics. Multiple clinical trials and real-world studies have confirmed it to be a safe, effective systemic therapy suitable for long-term use. For physicians, Dupixent®“Its rapid onset, safety, and durable efficacy make it a powerful weapon against disease; for patients, it further fosters willingness and confidence in long-term treatment, significantly improving adherence.”
The adjustment of retail prices prior to the formal implementation of medical insurance coverage will significantly reduce patients’ medication burden, improve accessibility to treatments, and provide a “lever” for the timely initiation of standardized therapy. Professor Zhang Jianzhong pointed out, “Atopic dermatitis is a lifelong condition; early initiation of standardized treatment can delay the atopic march.”[2]Dupixent®"Inclusion in the National Reimbursement Drug List, coupled with an early price reduction, not only addresses the urgent need of patients with atopic dermatitis for breakthrough innovative therapies but also plays a crucial role in enhancing medication adherence and promoting standardized disease management."
Severe Itching with Recurrent Episodes: Follow the Clues and Seek Standardized Treatment Early
Dr. Zhao Yan, Associate Chief Physician of the Department of Dermatology at Peking University People’s Hospital, stated that over the past 30 years, the prevalence of atopic dermatitis has gradually increased, characterized by high incidence but low diagnosis rates. In fact, many cases clinically diagnosed as eczema, refractory eczema, or chronic eczema are essentially atopic dermatitis. This misclassification stems from historical insufficient understanding and diagnostic recognition of atopic dermatitis. Atopic dermatitis is a type 2 inflammatory disease driven primarily by IL-4 and IL-13. Although it is now recognized in clinical practice as a distinct, clearly diagnosable disease entity, many patients continue to be misdiagnosed.
Professor Zhang Jianzhong stated, “Untimely and non-standardized diagnosis and treatment have become significant contributors to the recurrent nature of atopic dermatitis. Even among patients with a confirmed diagnosis, therapeutic outcomes are often unsatisfactory, with the disease remaining uncontrolled over the long term. Many patients, after cycling through various treatments without improvement, may even abandon therapy. In recent years, China has adopted highly effective and safe approaches for the diagnosis, treatment, and prevention of atopic dermatitis, enabling patients to receive a clear diagnosis by seeking care at appropriate medical institutions. With the official launch of the Atopic Dermatitis Diagnosis and Treatment Map in Beijing, patients can now follow this guide to access standardized care.”
Poorly controlled moderate-to-severe atopic dermatitis can significantly impair the quality of life for both patients and their families. Professor Zhang Jianzhong reminds that when patients experience recurrent episodes of intense pruritus and skin dryness, followed by severe skin lesions and sleep disruption, they should seek prompt diagnosis and targeted treatment at specialized hospitals or clinics with appropriate diagnostic and therapeutic capabilities. This approach can effectively alleviate or reduce disease recurrence and simultaneously help prevent the development of comorbid conditions such as allergic asthma and allergic rhinitis.
Dupixent®Prescriptions are now available at nearly 200 hospitals and over 120 pharmacies across 55 cities, including Beijing, Shanghai, Guangzhou, Chengdu, Wuhan, and Shenyang. Patients can also purchase medications through internet hospital platforms with prescriptions issued by doctors at select hospitals, with cold-chain delivery services provided.Arrived home.
(Dupixent®This is a prescription medication; please use it strictly in accordance with your physician’s instructions. For professional medical advice, consult a qualified physician at any hospital.
Hospital
Affiliated Pharmacy
Pharmacy Address
Beijing Hospital - AD Clinic
Beijing Dexinhang Medical Insurance Brand-New Pharmacy
Chongwenmen Store Co., Ltd.
No. 1 Dahua Road, Dongcheng District, Beijing; No. 3 and No. 7 Dongjiaominxiang
Building No., 1st Floor, Room 0122
China-Japan Friendship Hospital, Beijing - MDT Outpatient Clinic
Beijing Dongyinghua Pharmacy Co., Ltd.
Yinghuayuan East Street, Chaoyang District, Beijing (China-Japan Friendship Hospital)
Rooms 52 and 53, 1st Floor, Building 24
Beijing Friendship Hospital, Capital Medical University - AD Specialty Clinic
Beijing Youyi Renbo Pharmacy
No. 95, Yong'an Road, Xicheng District, Beijing
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences - AD Specialty Clinic
Beijing Xiehe Fine Chemical Products
Xiehe Pharmacy Co., Ltd.
No. 69-5, Dongdan North Street, Dongcheng District, Beijing
Hospital
DTPPharmacy and Address
Peking University Third Hospital - Pruritus Clinic
Beijing Dexinhang Medical Insurance Brand-New Pharmacy Co., Ltd. Andingmen Branch
(No. 96, Andingmen Inner Street, Dongcheng District, Beijing)
Beijing Jinxiang Grand Pharmacy Pharmaceutical Chain Co., Ltd. Xidan Store
(No. 114, Xidan North Street, Xicheng District, Beijing)
Peking University People's Hospital - AD Specialized Clinic
Peking University First Hospital - AD Specialized Clinic, MDT Outpatient Clinic
[1] Curr Dermatol Rep. 2017;6(3):204-10.
[2] J Allergy Clin Immunol . 2019 Jan;143(1)：46-55.